Gilead Doubles Down on Autoimmune “Immune Reset” With 2.2 Billion Dollar Ouro Buyout

Gilead Sciences Inc. (NASDAQ: GILD)  has agreed to acquire Ouro Medicines for 1.675 billion dollars in upfront cash, plus up to 500 million dollars in contingent milestone payments, bringing the total potential consideration to about 2.175 billion dollars. Ouro is a privately held biotechnology company developing BCMAxCD3 T cell engager therapies for autoimmune diseases, with lead candidate OM336 (gamgertamig) designed to enable rapid B cell depletion via subcutaneous administration. OM336 is in Phase 1/2 clinical development and has received both Fast Track and Orphan Drug Designation from the FDA for autoimmune hemolytic anemia and immune thrombocytopenia, reflecting the high unmet need in these severe autoimmune indications.

Strategic collaboration with Galapagos

A key feature of the transaction is Gilead’s planned strategic collaboration with Galapagos around the Ouro portfolio, which meaningfully shares both risk and cost. Under the proposed structure, Galapagos would fund 50 percent of the upfront cash and 50 percent of future milestones, effectively cutting Gilead’s economic exposure in half while preserving access to the asset’s upside. Galapagos would absorb substantially all of Ouro’s operating assets and employees and would assume responsibility for development through the initiation of registrational studies, after which Gilead and Galapagos would share development costs equally. Gilead would retain sole worldwide commercialization rights outside Greater China, where Keymed Biosciences already holds rights, and in return would pay Galapagos a royalty of 20 to 23 percent on net sales, aligning incentives while keeping commercial control with Gilead.

Implications for OM336 and pipeline

Mechanistically, OM336 is a BCMAxCD3 bispecific T cell engager intended to target BCMA‑expressing B‑cell populations that drive pathogenic autoantibody production, with the goal of delivering deep and possibly durable remission without chronic broad immunosuppression. Early Phase 1/2 data have shown efficacy signals in difficult‑to‑treat autoimmune hemolytic anemia and immune thrombocytopenia, supporting the hypothesis that controlled B‑cell depletion in these settings may translate into meaningful clinical benefit. If safety and durability of response continue to look favorable, OM336 could be expanded into additional autoimmune indications, giving Gilead and Galapagos a broader autoimmune franchise anchored on a potentially first‑in‑class mechanism.

Fit with Gilead’s broader BD push

Within Gilead’s strategy, the Ouro deal strengthens its inflammation and autoimmune portfolio while complementing its growing presence in T‑cell–based therapies following the recent Arcellx acquisition. In February 2026, Gilead agreed to acquire Arcellx for 115 dollars per share in cash plus a 5‑dollar contingent value right, an all‑in implied equity value of about 7.8 billion dollars that secures control of the anito‑cel CAR‑T program in oncology. Together, Arcellx and Ouro signal a renewed push by Gilead to own differentiated cell‑ and T‑cell–engager platforms across both cancer and autoimmune disease, using business development to drive long‑term growth beyond its legacy HIV and antiviral franchises.

How an investor might frame it

From an investor’s standpoint, the Ouro transaction represents a relatively modest upfront deployment of capital compared with the Arcellx deal, made even more capital‑efficient by the 50 percent cost‑sharing arrangement with Galapagos. The core risk‑reward hinges on the safety profile of repeated B‑cell depletion, the durability of responses in autoimmune hemolytic anemia and immune thrombocytopenia, and the ability to broaden OM336 into additional immune‑mediated diseases that could justify multibillion‑dollar peak sales. If the emerging clinical profile continues to de‑risk the mechanism, this structure gives Gilead meaningful upside participation in a potentially important autoimmune platform while preserving balance‑sheet flexibility for future deals.